Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

World Journal of Surgical Oncology

Research

Zhixiong Yang¹  Aibing Wu¹  Kunpeng Wu²  Qiaozhu Yang³  Yi Liu⁴ 

[1] Cancer Center, Affiliated Hospital of Guangdong Medical College, 57 Renmin Road, Zhanjiang, PR, China;Cancer Center, Affiliated Hospital of Guangdong Medical College, 57 Renmin Road, Zhanjiang, PR, China;Cancer Center, Heyuan People’s hospital, Heyuan, PR, China;Department of Gynecology and Obstetrics, Women and Child Care Institute of Heyuan, Heyuan, PR, China;Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical College, Zhanjiang, PR, China;

关键词: breast cancer;    neoadjuvant chemotherapy;    pathologic complete response;    meta-analysis;   

DOI  :  10.1186/1477-7819-12-95

 received in 2014-02-16, accepted in 2014-04-04,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundTriple-negative breast cancer (TNBC) is a special subtype of breast cancer that is characterized by poor prognosis, strong tumor invasion and a high pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC). The pCR rate is a prognostic factor for TNBC. We aimed to evaluate the relationship between pCR and TNBC after NAC and originally tried to identify factors related to achieving pCR for TNBC using a meta-analysis.MethodsWe systematically searched the literature for pCR and breast cancer after NAC and carefully identified eligibility criteria. The association between pCR and breast cancer subtypes was estimated using Review Manager, while pCR rates for TNBC and non-TNBC were determined using Meta-Analyst.ResultsThis analysis included a total of 9,460 cases from 27 studies. The summary odds ratio estimating the relationship between pCR and breast cancer subtypes (TNBC vs non-TNBC) was 3.02 (95% confidence interval (CI), 2.66 to 3.42). The TNBC pCR rate was 28.9% (95% CI, 27.0 to 30.8%) and the non-TNBC was 12.5% (95% CI, 11.7 to 13.4%). From subgroup analyses, we identified the factors associated with the highest pCR rates for TNBC.ConclusionsTNBC has a higher pCR rate than non-TNBC. In the NAC setting, these factors of platinum-containing, more than six cycles, four kinds of drugs, 16 weeks’ treatment duration and sequential chemotherapy may contribute to increasing the pCR rate.

【 授权许可】

CC BY   
© Wu et al.; licensee BioMed Central Ltd. 2014